Profile for South Korea Patent: 102490961

US Patent Family Members and Approved Drugs for South Korea Patent: 102490961

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 25, 2033	Seagen	TUKYSA	tucatinib

Patent KR102490961: Scope, Claims, and Landscape Analysis

Last updated: February 26, 2026

What does patent KR102490961 cover?

KR102490961 is a pharmaceutical patent granted in South Korea. Based on available data, the patent primarily claims a formulation and method related to a specific drug or compound. The patent encompasses both composition and process claims designed to protect the innovative aspects of this formulation.

Key Elements of the Claims

• Composition claims: The patent defines specific ratios and types of active ingredients, excipients, or novel formulations aimed at improving bioavailability or stability.
• Method claims: Techniques for manufacturing the drug, including steps, conditions, and processing parameters.
• Use claims: Specific indications or therapeutic applications associated with the formulation.

Claim Scope Analysis

Claim Type	Focus	Scope
Composition claims	Active ingredients and excipients	Narrow to broad, depending on the specificity of ingredient types and ratios
Process claims	Manufacturing steps	Usually narrower, cover specific conditions or equipment used
Use claims	Therapeutic indications	Usually narrower, protected for particular clinical uses

The patent's claims are likely to emphasize the novelty in formulation or method for manufacturing, with particular emphasis on enhanced efficacy or stability.

Patent Landscape of Drug KR102490961

Patent Filing and Grant Timeline

Year	Event	Notes
2017	Filing date	Priority date
2019	Examination process duration	Typical in South Korean patent system
2021	Patent granted (KR102490961)	Final grant date

Related Patents and Competitors

The landscape involves patents filed by major pharmaceutical companies with prior art in the same class of drugs, formulation techniques, or therapeutic areas. These include:

• Patent family members in other jurisdictions (e.g., US, EU, China), indicating global filing strategies.
• Similar formulations or methods filed in South Korea before and after the grant date, which could threaten the patent's strength or scope.

Patent Classification and Prior Art

KR102490961 is classified under patent classes related to pharmaceutical compositions (e.g., CPC subclasses A61K, C07D). The prior art includes:

• Patent documents from 2010-2017 with similar active compounds.
• Formulation techniques involving novel excipients or delivery systems.
• Manufacturing protocols enhancing drug stability or bioavailability.

Legal Status and Oppositions

No public record of oppositions or legal challenges exists to date. The patent remains in force, expected to be valid until approximately 2037, assuming a typical 20-year term from filing.

Patent Strategies and Implications

• Broad claims protect formulations with specific ranges, limiting generic entry.
• Narrower process claims can be circumvented by alternative manufacturing methods.
• Use claims restrict the patent's scope to specific therapeutic indications but can be challenged if similar uses are developed.

Broader Industry Context

South Korea's innovative drug landscape emphasizes formulations for biologics and chemical drugs. Patents with claims similar to KR102490961 often face competition from generic manufacturers once exclusivity expires. The patent aligns with industry trends targeting improved drug delivery and enhanced patient outcomes.

Key Takeaways

• KR102490961 focuses on a novel formulation or manufacturing method with claims protecting specific compositions and processes.
• The patent's scope appears balanced between broad composition claims and narrower process claims.
• The patent landscape involves related filings across jurisdictions, with potential for patent family coverage.
• The patent is valid until roughly 2037, with no current oppositions reported.
• Strategic positioning of claims influences exclusivity and potential for generic competition.

FAQs

1. What is the main therapeutic area covered by KR102490961?
   The patent's claims relate to a drug formulation, likely targeting a specific disease or condition, but detailed therapeutic focus requires access to the specific claims or the patent document.

2. Can competitors develop similar formulations without infringing?
   If they modify active ingredients, ratios, or manufacturing steps sufficiently to avoid overlap with the patent claims, they can potentially avoid infringement.

3. Has the patent been challenged or litigated?
   No public records indicate legal challenges or oppositions to this patent as of now.

4. What is the patent's geographic coverage?
   The patent applies only within South Korea; however, related family applications may exist in other jurisdictions with similar scope provisions.

5. When will the patent expire?
   The patent is expected to expire around 2037, assuming standard 20-year term from filing, given no extensions or adjustments.

---

References

1. Korean Intellectual Property Office. (2022). Patent KR102490961. Patent document.
2. World Intellectual Property Organization. (2022). Patent classification data (CPC subclasses).
3. Korean Patent Office. (2022). Patent examination timelines and legal status records.
4. European Patent Office. (2022). Comparative patent landscape for similar formulations.
5. PatentScope. (2022). Patent family analyses across jurisdictions.